Interestingly, subdividing AML with MRC cases that are associated with complex karyotypes into typical (those harboring 5q, 7q and/or 17p abnormalities) and atypical (those without these abnormalities) shows that AML with atypical complex karyotypes tend to have PHF6 mutations more frequently, TP53 mutations less frequently, be younger, have a higher WBC and blast percentage, and higher complete remission and overall survival rates (61). Here, TP53 is linked to acute myeloid leukemia.